Over the last 2 decades, novel therapies targeting several immune pathways have been
developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti …

Background Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and
are often restricted by safety concerns. Biologics may address the unmet need for improved …

Atopic dermatitis (AD) is the most common inflammatory skin disease, but treatment options
for moderate‐to‐severe disease are limited. Ustekinumab is an IL‐12/IL‐23p40 antagonist …

Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family that regulates signal
transduction downstream of receptors for the IL-23/IL-12 pathways and type I interferon …

Objective. To evaluate the longer-term safety and efficacy of secukinumab, a fully human
monoclonal antiinterleukin-17A antibody, in patients with rheumatoid arthritis. Methods. In …

Psoriasis is an autoimmune disease mediated by disturbed T cells and other immune cells,
and is defined by deep-red, well-demarcated skin lesions. Due to its varied etiologies and …

Introduction: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for
inflammatory bowel disease (IBD). The monoclonal antibody targeting the shared p40 …

Background: Psoriasis is a genetically predisposed autoimmune disease mediated by
cytokines released by the activated immune cells. It manifests inflammatory, scaly red or …

Objectives: We describe the use of ustekinumab for 4 patients with pediatric Crohn disease
treated at the Seattle Children's Hospital Inflammatory Bowel Disease Center. Methods: A …

Cytokine-driven inflammation underlies the pathobiology of a wide array of infectious and
immune-related disorders. The TNFR-associated factor (TRAF) proteins have a vital role in …